<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Anticoagulation versus placebo for heart failure in sinus rhythm - Shantsila, E - 2021 | Cochrane Library</title> <meta content="Anticoagulation versus placebo for heart failure in sinus rhythm - Shantsila, E - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003336.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Anticoagulation versus placebo for heart failure in sinus rhythm - Shantsila, E - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003336.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD003336.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Anticoagulation versus placebo for heart failure in sinus rhythm" name="citation_title"/> <meta content="Eduard Shantsila" name="citation_author"/> <meta content="City Hospital, Sandwell and West Birmingham Hospitals NHS Trust" name="citation_author_institution"/> <meta content="Monika Kozieł" name="citation_author"/> <meta content="Gregory YH Lip" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="gregory.lip@liverpool.ac.uk" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD003336.pub4" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/05/18" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003336.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003336.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003336.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Oral; Anticoagulants [adverse effects, *therapeutic use]; Aspirin [therapeutic use]; Cardiomyopathy, Dilated [*complications]; Chronic Disease; Heart Failure [*complications, mortality]; Heart Rate; Hemorrhage [chemically induced]; Placebo Effect; Placebos [therapeutic use]; Randomized Controlled Trials as Topic; Rivaroxaban [therapeutic use]; Stroke [prevention &amp; control]; Thromboembolism [etiology, mortality, *prevention &amp; control]; Warfarin [adverse effects, therapeutic use]" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD003336.pub4&amp;doi=10.1002/14651858.CD003336.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="Xx9QLps0";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD003336\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD003336\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANT","ru","ko","ms","hr","fa","fr","pl"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD003336.pub4",title:"Anticoagulation versus placebo for heart failure in sinus rhythm",firstPublishedDate:"May 18, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Heart Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003336.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003336.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD003336.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD003336.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003336.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD003336.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD003336.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD003336.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD003336.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD003336.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2844 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD003336.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0079"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0041"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-sec-0073"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/appendices#CD003336-sec-0084"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/table_n/CD003336StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/table_n/CD003336StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Anticoagulation versus placebo for heart failure in sinus rhythm</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information#CD003336-cr-0004">Eduard Shantsila</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information#CD003336-cr-0005">Monika Kozieł</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information#CD003336-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Gregory YH Lip</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information/en#CD003336-sec-0106">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 18 May 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD003336.pub4">https://doi.org/10.1002/14651858.CD003336.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD003336-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003336-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003336-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003336-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003336-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003336-abs-0005">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD003336-abs-0001" lang="en"> <section id="CD003336-sec-0001"> <h3 class="title" id="CD003336-sec-0001">Background</h3> <p>People with chronic heart failure (HF) are at risk of thromboembolic events, including stroke, pulmonary embolism, and peripheral arterial embolism; coronary ischaemic events also contribute to the progression of HF. The use of long‐term oral anticoagulation is established in certain populations, including people with HF and atrial fibrillation (AF), but there is wide variation in the indications and use of oral anticoagulation in the broader HF population. </p> </section> <section id="CD003336-sec-0002"> <h3 class="title" id="CD003336-sec-0002">Objectives</h3> <p>To determine whether long‐term oral anticoagulation reduces total deaths and stroke in people with heart failure in sinus rhythm. </p> </section> <section id="CD003336-sec-0003"> <h3 class="title" id="CD003336-sec-0003">Search methods</h3> <p>We updated the searches in CENTRAL, MEDLINE, and Embase in March 2020. We screened reference lists of papers and abstracts from national and international cardiovascular meetings to identify unpublished studies. We contacted relevant authors to obtain further data. We did not apply any language restrictions. </p> </section> <section id="CD003336-sec-0004"> <h3 class="title" id="CD003336-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCT) comparing oral anticoagulants with placebo or no treatment in adults with HF, with treatment duration of at least one month. We made inclusion decisions in duplicate, and resolved any disagreements between review authors by discussion, or a third party. </p> </section> <section id="CD003336-sec-0005"> <h3 class="title" id="CD003336-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trials for inclusion, and assessed the risks and benefits of antithrombotic therapy by calculating odds ratio (OR), accompanied by the 95% confidence intervals (CI). </p> </section> <section id="CD003336-sec-0006"> <h3 class="title" id="CD003336-sec-0006">Main results</h3> <p>We identified three RCTs (5498 participants). One RCT compared warfarin, aspirin, and no antithrombotic therapy, the second compared warfarin with placebo in participants with idiopathic dilated cardiomyopathy, and the third compared rivaroxaban with placebo in participants with HF and coronary artery disease. </p> <p>We pooled data from the studies that compared warfarin with a placebo or no treatment. We are uncertain if there is an effect on all‐cause death (OR 0.66, 95% CI 0.36 to 1.18; 2 studies, 324 participants; low‐certainty evidence); warfarin may increase the risk of major bleeding events (OR 5.98, 95% CI 1.71 to 20.93; number needed to treat for an additional harmful outcome (NNTH) 17; 2 studies, 324 participants; low‐certainty evidence). None of the studies reported stroke as an individual outcome. </p> <p>Rivaroxaban makes little to no difference to all‐cause death compared with placebo (OR 0.99, 95% CI 0.87 to 1.13; 1 study, 5022 participants; high‐certainty evidence). Rivaroxaban probably reduces the risk of stroke compared to placebo (OR 0.67, 95% CI 0.47 to 0.95; number needed to treat for an additional beneficial outcome (NNTB) 101; 1 study, 5022 participants; moderate‐certainty evidence), and probably increases the risk of major bleeding events (OR 1.65, 95% CI 1.17 to 2.33; NNTH 79; 1 study, 5008 participants; moderate‐certainty evidence). </p> </section> <section id="CD003336-sec-0007"> <h3 class="title" id="CD003336-sec-0007">Authors' conclusions</h3> <p>Based on the three RCTs, there is no evidence that oral anticoagulant therapy modifies mortality in people with HF in sinus rhythm. The evidence is uncertain if warfarin has any effect on all‐cause death compared to placebo or no treatment, but it may increase the risk of major bleeding events. There is no evidence of a difference in the effect of rivaroxaban on all‐cause death compared to placebo. It probably reduces the risk of stroke, but probably increases the risk of major bleedings. </p> <p>The available evidence does not support the routine use of anticoagulation in people with HF who remain in sinus rhythm. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD003336-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD003336-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD003336-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD003336-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD003336-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD003336-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD003336-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD003336-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD003336-abs-0013">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD003336-abs-0004">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD003336-abs-0003">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD003336-abs-0002" lang="en"> <h3>What is the evidence for the benefit and harms of anticoagulants for heart failure?</h3> <p><b>Background</b> </p> <p>When the heart’s ability to pump blood is reduced, it is called heart failure (HF). When this happens, some people will develop severe clotting problems (called thromboembolism) in the lungs, legs, and brain. This happens because the blood is flowing more slowly, inflammation is increasing, and there is an overproduction of clotting molecules. These clots can cause stroke, lung or leg damage, or even death. </p> <p><b>Why is the question important?</b> </p> <p>There are strong blood‐thinning medications, called anticoagulants, which are successfully used in people with different clotting problems, such as those with HF who also have irregular heart beats (an arrhythmia called atrial fibrillation). At present, there are no data to recommend the use of anticoagulants to avoid clotting problems in people with HF who have regular heart beats (know as sinus rhythm). In this analysis, we assessed studies that tested anticoagulants in these people to avoid death, death from heart problems, and other severe clotting problems. </p> <p><b>How did we identify and evaluate the evidence?</b> </p> <p>We searched electronic databases of studies (CENTRAL, MEDLINE, and Embase). We looked for randomised studies (like tossing a coin) that compared anticoagulant tablets with no treatment or a placebo (tablet with no drug inside) in people with HF who were in sinus rhythm. </p> <p><b>What did we find?</b> </p> <p>We found three randomised trials, with 5498 participants, which we used for analysis. </p> <p><b>What does this mean?</b> </p> <p>Based on the three randomised trials, we are uncertain about the risk of dying between people who took warfarin and those who did not. However, people who took warfarin may have been more likely to have episodes of major bleeding. The evidence suggested that there was no difference in the risk of dying for people who took rivaroxaban compared with those who did not. Rivaroxaban probably reduced the risk of stroke, but the risk of episodes of major bleeding was higher than in those who did not take rivaroxaban. </p> <p>Our analysis does not support the routine use of anticoagulation in people with HF who remain in sinus rhythm. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The literature is current to March 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD003336-sec-0079" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD003336-sec-0079"></div> <h3 class="title" id="CD003336-sec-0080">Implications for practice</h3> <section id="CD003336-sec-0080"> <p>Anticoagulation therapy carries some risk, so clinicians contemplating antithrombotic therapy for prophylaxis against stroke and thromboembolic events in people with heart failure (HF) must balance the benefit of risk reduction against the risks of potentiating haemorrhage with vitamin K antagonists or non‐vitamin K antagonist oral anticoagulants therapy. The evidence is uncertain if warfarin has any effect on all‐cause death compared to no treatment or placebo, but it may increase the risk of major bleeding events. </p> <p>Rivaroxaban compared to placebo probably reduces the risk of stroke. There is evidence of no difference in rivaroxaban's effect on all‐cause death, but it probably increases the risk of major bleeding events when compared to placebo. </p> <p>The three existing randomised studies do not support the routine use of oral anticoagulation in people with heart failure who remain in sinus rhythm.  </p> </section> <h3 class="title" id="CD003336-sec-0081">Implications for research</h3> <section id="CD003336-sec-0081"> <p>The clinical question of comparing anticoagulation with placebo for people with heart failure (HF) in sinus rhythm is now an outdated scope, and future research will be directed towards randomised trials comparing antiplatelet agents versus control or anticoagulation. Data from large scale RCTs in ambulant people with HF are needed to evaluate the effectiveness of anticoagulant therapy and antiplatelet therapy. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD003336-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD003336-sec-0008"></div> <div class="table" id="CD003336-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with heart failure in sinus rhythm<br/><b>Setting:</b> outpatient clinics<br/><b>Intervention:</b> warfarin<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with warfarin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/>(84 to 231) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.66<br/>(0.36 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low certainty<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Stroke was not reported as an individual outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/143</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11/181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 5.98<br/>(1.71 to 20.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low certainty<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 in the control arm for major bleeding events. It is not based on the estimated relative effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice – once for imprecision, and once for inconsistency due to high heterogeneity<br/><sup>b</sup>Downgraded twice for imprecision, due to the small sample size and low event rate </p> <p><sup>c</sup>A major bleeding event is defined by the International Society on Thrombosis and Haemostasis as overt bleeding associated with a decrease in haemoglobin level of at least 2 g/dL, transfusion of two or more units of packed red cells or whole blood, bleeding in a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, or retroperitoneal), or a fatal outcome. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD003336-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rivaroxaban compared to placebo in people with heart failure in sinus rhythm</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rivaroxaban compared to placebo in people with heart failure in sinus rhythm</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with heart failure in sinus rhythm<br/><b>Setting:</b> hospital or outpatient clinic<br/><b>Intervention:</b> rivaroxaban<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rivaroxaban</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/>(204 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.99<br/>(0.87 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5022<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High certainty</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(14 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.67<br/>(0.47 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5022<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate certainty<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/>(23 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.65<br/>(1.17 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5008<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate certainty<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for imprecision, due to very low event rates.<br/><sup>b</sup>A major bleeding event is defined by the International Society on Thrombosis and Haemostasis as overt bleeding associated with a decrease in haemoglobin level of at least 2 g/dL, transfusion of two or more units of packed red cells or whole blood, bleeding in a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, or retroperitoneal), or a fatal outcome. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD003336-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD003336-sec-0009"></div> <section id="CD003336-sec-0010"> <h3 class="title" id="CD003336-sec-0010">Description of the condition</h3> <p>Chronic heart failure (HF) is a growing clinical and social problem. HF has an estimated prevalence of approximately 1% to 2% of the adults in developed countries, reaching ≥ 10% among people over 70 years of age (<a href="./references#CD003336-bbs2-0041" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, ESC Scientific Document Group 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016 July;37:2129–200.">Ponikowski 2016</a>). It is associated with high morbidity and annual mortality, with rates higher than 30% in people with severe symptoms (<a href="./references#CD003336-bbs2-0005" title="CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine1987;316(23):1429-35. [DOI: 10.1056/NEJM198706043162301] [PMID: 2883575]">CONSENSUS 1987</a>). </p> <p>HF predisposes a person to stroke and thromboembolism, including pulmonary embolism and peripheral arterial embolism. These thromboembolic events contribute to the high morbidity in HF (<a href="./references#CD003336-bbs2-0007" title="FusterV , GershBJ , GiulianiER , TajikAJ , BradenburgRO , FryeRL . The natural history of idiopathic dilated cardiomyopathy. American Journal of Cardiology1981;47:525-31. ">Fuster 1981</a>; <a href="./references#CD003336-bbs2-0010" title="KyrlePA , KorningerC , GossingerH , GlogarD , LechnerK , NiessnerH , et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thrombosis and Haemostasis1985;54:521-3. ">Kyrle 1985</a>). Ischaemic and thromboembolic events, particularly stroke, myocardial ischaemia, and myocardial infarction (MI), also contribute to the high hospital admission rates for people with HF (<a href="./references#CD003336-bbs2-0023" title="BrownA , ClelandJGF . Influence of concomitant disease on patterns of hospitalisation in patients with heart failure discharged from Scottish hospitals in 1995. European Heart Journal1998;19:1063-9.">Brown 1998</a>). The outcomes for people with HF remain unsatisfactory. The healthcare and mortality burden of HF are substantial. In the USA, the comorbid HF event rate increased between 2006 and 2014, which was also associated with rising healthcare costs (<a href="./references#CD003336-bbs2-0033" title="JacksonSL , TongX , KingRJ , LoustalotF , HongY , RitcheyMD . National burden of heart failure events in the United States, 2006 to 2014. Circulation. Heart Failure 2018 December;11(12):e004873.">Jackson 2018</a>). </p> <p>According to the European Society of Cardiology (ESC) guidelines, HF comprises people with normal left ventricular ejection fraction (HF with preserved EF (HFpEF), when EF ≥ 50%; HF with mid‐range EF (HFmrEF), when EF = 40% to 49%; and HF with reduced EF (HFrEF), when EF &lt; 40% (<a href="./references#CD003336-bbs2-0041" title="PonikowskiP , VoorsAA , AnkerSD , BuenoH , ClelandJGF , CoatsAJS , et al, ESC Scientific Document Group 2016. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. European Heart Journal 2016 July;37:2129–200.">Ponikowski 2016</a>)). The previous ESC guidelines divided people with HF into those with reduced EF (EF ≤ 35%), and preserved EF (EF ≥ 50% (<a href="./references#CD003336-bbs2-0037" title="McMurrayJJ , AdamopoulosS , AnkerSD , AuricchioA , BöhmM , DicksteinK , et al, ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal 2012 Jul;33(14):1787-847; Erratum in: European Heart Journal. 2013 Jan;34(2):158. [DOI: 10.1093/eurheartj/ehs104]">McMurray 2012</a>)). As discussed previously, HF predisposes people to thromboembolic events. </p> <p>People hospitalised due to HF have an increased risk of venous thromboembolism (VTE) because of vascular abnormalities, increased coagulability, and impaired blood flow (<a href="./references#CD003336-bbs2-0029" title="HaasS . Venous thromboembolism in medical patients – the scope of the problem. Seminars in Thrombosis and Hemostasis December 2003;29(Suppl 1):17-21.">Haas 2003</a>). In cases of no thromboprophylaxis, the incidence of VTE ranges from 4% to 26% in people with decompensated HF. In one study, participants with more severe HF (defined by high N‐terminal pro‐B type natriuretic peptide plasma concentration) were at elevated risk of VTE (<a href="./references#CD003336-bbs2-0038" title="MebazaaA , SpiroTE , BüllerHR , HaskellL , HuD , HullR , et al. Predicting the risk of venous thromboembolism in patients hospitalized with heart failure. Circulation 2014 June;130(5):410-8.">Mebazaa 2014</a>). In people with new onset HF, the cumulative incidence of VTE was 1.4% at 30 days, 2.5% at 1 year, and 10.5% at 5 years (<a href="./references#CD003336-bbs2-0046" title="SmilowitzNR , ZhaoQ , WangL , ShresthaS , BaserO , BergerJS . Risk of venous thromboembolism after new onset heart failure. Scientific Reports 2019 November;9(1):17415.">Smilowitz 2019</a>). </p> </section> <section id="CD003336-sec-0011"> <h3 class="title" id="CD003336-sec-0011">Description of the intervention</h3> <p>Oral anticoagulants include vitamin K antagonists (VKA) and non‐vitamin K antagonist oral anticoagulants (NOAC). VKA inhibit the synthesis of the active forms of vitamin K‐dependent procoagulant proteins: prothrombin, factor VII, IX, and X, and protein C and S. Its narrow therapeutic interval, fluctuations of dose‐response relationship, and interactions with food and drugs for concomitant diseases, limit the use of VKA. Warfarin blocks vitamin K. NOACs include: dabigatran, rivaroxaban, apixaban, and edoxaban. Dabigatran is a direct thrombin inhibitor. Rivaroxaban, apixaban, and edoxaban act as factor Xa inhibitors. NOACs differ from VKA: they have rapid onset of action, fewer drug interactions, and their activity is not influenced by dietary vitamin K intake. They also have a predictable anticoagulant effect, and thus, they do not need routine coagulation monitoring. </p> <p>HF has not been well defined in NOAC trials. There were numerous definitions based on reported symptoms, and occasionally, on left ventricular EF. People with HF may be prone to VKA instability and drug interactions, which happen to a lesser extent with NOACs. NOACs are an efficient and safe alternative to VKA in people with HF. The available data provide assurance that the relative risks and benefits of NOACs versus VKAs likely apply to people with HF. However, a more homogeneous definition of HF should be implemented in future trials. In people with HF and previous thromboembolism, newly diagnosed intracardiac thrombus, and right HF with concomitant pulmonary hypertension, anticoagulation may potentially be considered, but evidence is limited. The question whether to use oral anticoagulants (OAC) in people with HF and extensive infarct scar remains open, and needs further research. </p> <p>There is evidence of benefit from long‐term oral anticoagulation in certain groups of people with HF. For instance, oral anticoagulation is extremely effective in reducing stroke and other embolic events in people with HF in atrial fibrillation (<a href="./references#CD003336-bbs2-0021" title="The Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF) Investigators. The effect of low-dose warfarin on the risk of stroke in patients with non-rheumatic atrial fibrillation. New England Journal of Medicine1990;323:1505-11.">BAATAF 1990</a>; <a href="./references#CD003336-bbs2-0040" title="PetersenP , BoysenG , GodtfredsenJ , AndersenED , AndersenB . Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet1989;I:175-9.">Petersen 1989</a>; <a href="./references#CD003336-bbs2-0047" title="Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke Prevention in Atrial Fibrillation Investigators. Circulation1991;84:527-39.">SPAF 1991</a>). The role of anticoagulation in the broader HF population is less well established. There is wide variation in the use of oral anticoagulants in people with HF (<a href="./references#CD003336-bbs2-0026" title="EdepME , ShahNB , MassieBM . Differences between primary care physicians and cardiologists in the management of congestive heart failure: relationship to practice guidelines. Journal of the American College of Cardiology1997;30:518-26.">Edep 1997</a>). </p> </section> <section id="CD003336-sec-0012"> <h3 class="title" id="CD003336-sec-0012">How the intervention might work</h3> <p>Oral anticoagulation has been associated with a reduction in the number of thromboembolic events in various cardiovascular disease states, but the potential risks of bleeding must also be considered. Importantly, the control of anticoagulation is reported to be more difficult, and bleeding complications more frequent in HF, as a result of hepatic congestion and potential drug interactions (<a href="./references#CD003336-bbs2-0024" title="DavisFB , EstruchMT , Samson-CorveraEB , VoigtGC , TobinJD . Management of anticoagulation in outpatients: experience with an anticoagulation service in a municipal hospital setting. Archives of Internal Medicine1977;137:197-202.">Davis 1977</a>; <a href="./references#CD003336-bbs2-0032" title="HustedS , AndraesenF . Problems encountered in long-term treatment with anticoagulants. Acta Medica Scandinavica1976;200:379-84.">Husted 1976</a>; <a href="./references#CD003336-bbs2-0034" title="LandefeldCS , GoldmanL . Major bleeding in outpatients treated with warfarin. Incidence and prediction by factors known at the start of outpatient therapy. American Journal of Medicine1989;87:144-52.">Landefeld 1989</a>). </p> <p>In clinical practice, people with HF in sinus rhythm have a high risk of thromboembolism and bleeding. Because there are no clear guideline recommendations for people with HF in sinus rhythm, the therapeutic decisions tend to be based on a case‐by‐case assessment, during which the physician takes into account factors including age, aetiology of HF, risk of bleeding, severity of functional impairment, cardiac remodelling, and the risk of drug non‐adherence (<a href="./references#CD003336-bbs2-0042" title="PozzoliM , Gonzalez-CostelloJ , Bayes-GenisA , SinagraG , AnkerSD , CoatsAJS , et al, ESC Heart Failure Long-Term Registry Investigators Group. Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure. European Journal of Heart Failure 2020 March;22(5):906-10. [DOI: 10.1002/ejhf.1789]">Pozzoli 2020</a>). Recent data indicate that CHA₂DS₂‐VASc and HAS‐BLED scores can be useful to predict thromboembolic and haemorrhagic events in those with HF in sinus rhythm (<a href="./references#CD003336-bbs2-0039" title="MelgaardL , Gorst-RsmussenA , LaneDA , RasmussenLH , LarsenTB , LipGY . Assessment of the CHA₂DS₂-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA2015;314:1030-8.">Melgaard 2015</a>; <a href="./references#CD003336-bbs2-0048" title="YeS , GhengB , LipGY , BuchsbaumR , SaccoRL , LevinB , et al, WARCEF Investigators. Bleeding risk and antithrombotic strategy in patients with sinus rhythm and heart failure with reduced ejection fraction treated with warfarin or aspirin. American Journal of Cardiology2015;116:904-12.">Ye 2015</a>). </p> <p>Stroke risk is linked with bleeding risk. There is evidence that thromboembolic factors, like older age, hypertension, or history of stroke are also bleeding risk factors. The benefits of OAC in the elderly are evident, despite their co‐morbidities, frailty, and increased risk of falls (<a href="./references#CD003336-bbs2-0020" title="AnnoniG , MazzolaP . Real-world characteristics of hospitalized frail elderly patients with atrial fibrillation: can we improve the current prescription of anticoagulants?Journal of Geriatric Cardiology: JGC2016;13(3):226-32.">Annoni 2016</a>; <a href="./references#CD003336-bbs2-0025" title="DeandreaS , BraviF , TuratiF , LucentaforteE , La VecchiaC , NegriE . Risk factors for falls in older people in nursing homes and hospitals. A systematic review and meta-analysis. Archives of Gerontology and Geriatrics2013;56(3):407-15.">Deandrea 2013</a>). </p> <p>Before initiation of OAC therapy, risk of bleeding should be evaluated. Potentially modifiable and non‐modifiable risk factors should be identified. High risk of bleeding should not justify withholding OAC. Modifiable bleeding risk factors should be managed, and systematically reassessed during regular and frequent visits. It should be highlighted that the risk of bleeding is dynamic, and should be re‐evaluated systematically (<a href="./references#CD003336-bbs2-0031" title="HindricksG , PotparaT , DagresN , ArbeloE , BaxJJ , Blomström-LundqvistC , et al, ESC Scientific Document Group. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal 2021 Feb 1;42(5):373-498. [DOI: 10.1093/eurheartj/ehaa612.]">Hindricks 2021</a>). It should be emphasised that absolute contraindications to OAC are rare. </p> </section> <section id="CD003336-sec-0013"> <h3 class="title" id="CD003336-sec-0013">Why it is important to do this review</h3> <p>Various small and large studies have addressed the incidence of ischaemic and thromboembolic events, and the risk factors associated with a high thromboembolic risk, although the reported incidence of these events appears to vary between studies, depending on the study methodologies and populations. Nevertheless, as an example, mild to moderate HF was associated with an annual stroke risk of approximately 1.5% compared with an annual stroke risk in the general population of less than 0.5%, whilst the annual risk of stroke increases to almost 4% in people with severe HF (<a href="./references#CD003336-bbs2-0005" title="CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine1987;316(23):1429-35. [DOI: 10.1056/NEJM198706043162301] [PMID: 2883575]">CONSENSUS 1987</a>; <a href="./references#CD003336-bbs2-0012" title="FalkR , PollackA , TandonPK , PackerM . The effect of warfarin on prevalence of stroke in severe heart failure. Journal of the American College of Cardiology1993;21(Suppl A):218A. ">PROMISE 1993</a>; <a href="./references#CD003336-bbs2-0014" title="Al-KhadraAS , SalemDN , RandWM , UdelsonJE , SmithJJ , KonstamMA . Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology1998;31(4):749-53. ">SOLVD 1998</a>; <a href="./references#CD003336-bbs2-0015" title="DunkmanWB , JohnsonGR , CarsonPE , BhatG , FarrellL , CohnJN , the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation1993;87(Suppl VI):94-101. ">V‐HeFT 1993</a>). </p> <p>The debate over the potential benefit of using oral anticoagulants in people with HF in sinus rhythm in clinical practice continues. The COMMANDER‐HF study added new evidence to this debate (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>). Thrombin plays a role in the adverse interplay between endothelial dysfunction, stasis, and inflammation, which are present in HF. The COMMANDER‐HF trial examins an intervention to modulate thrombin‐mediated 'crosstalk', a potential trigger of numerous negative feedback cycles, involving inflammation, endothelial dysfunction, and thrombosis in people with HFrEF and coronary artery disease (<a href="./references#CD003336-bbs2-0027" title="FerreiraJP , GirerdN , AlshalashS , KonstamMA , ZannadF . Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges . European Heart Journal2016;37:2455–64.">Ferreira 2016</a>). </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD003336-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD003336-sec-0014"></div> <p>To determine whether long‐term oral anticoagulation reduces total deaths and stroke in people with heart failure in sinus rhythm. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD003336-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD003336-sec-0015"></div> <section id="CD003336-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD003336-sec-0017"> <h4 class="title">Types of studies</h4> <p>We included parallel‐arm randomised controlled trials (RCTs), which were reported in full text.  </p> <p>We did not include cluster‐randomised studies, as the analysis aimed to assess the ability of the treatment to improve individual outcomes. We did not include cross‐over studies, to enable collection of the outcomes after completion of the trial treatment or withdrawal from it. Given the chronic nature of heart failure (HF), we also excluded studies with short treatment duration (i.e. less than one month). </p> </section> <section id="CD003336-sec-0018"> <h4 class="title">Types of participants</h4> <p>We included adults (≥ 18 years of age) with a diagnosis of HF. Participants with HF were defined clinically, and if possible, by a more objective assessment of the left ventricular systolic function (for example, echocardiography, radionuclide ventriculography, cardiac MRI). </p> <p>We excluded trials with participants with the following co‐morbidities and characteristics: diagnoses other than HF as inclusion criteria; trials with a mixed population if the subgroup of participants with HF was not analysed and reported separately (to analyse treatment effects specific to HF); atrial fibrillation (AF) at randomisation (as AF is an established indication for oral anticoagulation in people with or without HF). </p> </section> <section id="CD003336-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We included trials comparing oral anticoagulation with placebo or no treatment. The oral anticoagulants could include vitamin K antagonists (VKA; for example, warfarin) and non‐vitamin K antagonist oral anticoagulants (NOAC; for example, dabigatran, apixaban, rivaroxaban, or edoxaban). We excluded studies with co‐interventions (for example, beta‐blockers, ACE inhibitors). </p> </section> <section id="CD003336-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>The reporting of one or more of our outcomes of interest was not an inclusion criterion for the review. When a published report did not appear to report one of these outcomes, we accessed the trial protocol and contacted the trial authors to ascertain whether the outcomes were measured but not reported. We included relevant trials, which measured these outcomes but did not report the data at all, or not in a usable format, in the review as part of the narrative.  </p> <section id="CD003336-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD003336-list-0001"> <li> <p>All‐cause death</p> </li> <li> <p>Stroke</p> </li> </ul> </p> </section> <section id="CD003336-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD003336-list-0002"> <li> <p>Cardiovascular death (including sudden death)</p> </li> <li> <p>Myocardial infarction</p> </li> <li> <p>Pulmonary embolism</p> </li> <li> <p>Peripheral arterial embolism</p> </li> <li> <p>Major bleeding events (major bleeding was defined as fatal bleeding; symptomatic bleeding in a critical area or organ, such as intracranial, intraspinal, intraocular resulting in vision changes, retroperitoneal, intraarticular, pericardial, or intramuscular with compartment syndrome; bleeding causing a fall in haemoglobin level of 2 g/dL or more; bleeding leading to transfusion of two or more units of whole blood or red cells, or both (<a href="./references#CD003336-bbs2-0044" title="SchulmanS , KearonC , Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis: JTH 2005 Apr;3(4):692-4. [DOI: 10.1111/j.1538-7836.2005.01204.x]">Schulman 2005</a>)). </p> </li> </ul> </p> </section> </section> </section> <section id="CD003336-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD003336-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We identified trials through systematic searches of the following bibliographic databases:</p> <p> <ul id="CD003336-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2020, Issue 3) in the Cochrane Library (searched 20 March 2020); </p> </li> <li> <p>Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, MEDLINE Daily, and MEDLINE Ovid (1946 to 19 March 2020); </p> </li> <li> <p>Embase Ovid (1980 to week 11 2020).</p> </li> </ul> </p> <p>We updated the 2005 searches (<a href="./appendices#CD003336-sec-0085">Appendix 1</a>), in February 2010 (<a href="./appendices#CD003336-sec-0089">Appendix 2</a>), June 2013 (<a href="./appendices#CD003336-sec-0093">Appendix 3</a>), and March 2020 (<a href="./appendices#CD003336-sec-0097">Appendix 4</a>). </p> <p>We applied the Cochrane sensitivity‐maximising RCT filter to MEDLINE Ovid, and adapted it to use for Embase Ovid (<a href="./references#CD003336-bbs2-0035" title="LefebvreC , GlanvilleJ , BriscoeS , LittlewoodA , MarshallC , Metzendorf M-I, et al. Chapter 4: Searching for and selecting studies. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Lefebvre 2019</a>). </p> <p>We searched all databases from their inception to the present, and imposed no restriction on language of publication or publication status. We translated relevant foreign language papers. </p> <p>As records from Clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) and the World Health Organization (WHO) International Clinical Trials Registry platform (ICTRP; <a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) are included in CENTRAL, we did not search these clinical trials registers separately. </p> <p>We only considered adverse effects described in included studies.</p> </section> <section id="CD003336-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked reference lists of all included studies and relevant systematic reviews identified as part of the search, for additional references to trials. We also examined relevant retraction statements and errata for included studies. </p> </section> </section> <section id="CD003336-sec-0026"> <h3 class="title" id="CD003336-sec-0026">Data collection and analysis</h3> <section id="CD003336-sec-0027"> <h4 class="title">Updating this review</h4> <p>Over the course of the original review and updates, six authors (GYHL, IC, BJW, RP, ES, and MK) reviewed the inclusion criteria, the search strategies, the methodology criteria, and methods for pooling the data for this review. </p> </section> <section id="CD003336-sec-0028"> <h4 class="title">Contacting authors</h4> <p>In the rare instances where the authors disagreed over the grading and inclusion of studies, recourse was made to an additional author. When resolving the disagreement was not possible, we added the article to those ‘awaiting assessment’, and contacted the trial authors for clarification. However, there was no disagreement during the current update. </p> </section> <section id="CD003336-sec-0029"> <h4 class="title">Selection of studies</h4> <p>Two review authors (ES, MK) independently screened titles and abstracts to include all the potential studies we identified as a result of the search, and coded them as 'retrieve' (eligible or potentially eligible or unclear), or 'do not retrieve'. If there were any disagreements, they asked the third review author (GL) to arbitrate. We retrieved the full‐text study reports or publication, and two review authors independently screened the full text to identify studies for inclusion, and identify and record reasons for exclusion of the ineligible studies. We resolved any disagreement through discussion, or if required, we consulted a third person (GL). We identified and excluded duplicates, and collated multiple reports of the same study, so that each study, rather than each report, was the unit of interest in the review. We recorded the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (<a href="./references#CD003336-bbs2-0036" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , Gøtzsche PC, IoannidisJP , et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Medicine2009;6(7):e1000100.">Liberati 2009</a>). </p> </section> <section id="CD003336-sec-0030"> <h4 class="title">Data extraction and management</h4> <p>We used a data collection form for study characteristics and outcome data, which was piloted on at least one study in the review. One review author (MK) extracted the following study characteristics from included studies. </p> <p> <ol id="CD003336-list-0004"> <li> <p>Methods: study design, total duration of study, details of any 'run‐in' period, number of study centres and location, study setting, and date of study </p> </li> <li> <p>Participants: N randomised, N lost to follow‐up or withdrawn, N analysed, mean age, age range, gender, aetiology of HF, left ventricular ejection fraction (LVEF), inclusion criteria, and exclusion criteria </p> </li> <li> <p>Interventions: intervention, comparison, concomitant medications, and excluded medications</p> </li> <li> <p>Outcomes: primary and secondary outcomes specified and collected, and time points reported </p> </li> <li> <p>Notes: funding for trial, and notable conflicts of interest of trial authors</p> </li> </ol> </p> <p>Two review authors (ES, MK) independently extracted outcome data from the included studies. We resolved disagreements by consensus, with a provision of involving a third person (GL), would it be required. One review author (MK) transferred data into the Review Manager 5 file (<a href="./references#CD003336-bbs2-0043" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We double‐checked that data were entered correctly by comparing the data presented in the review with the data extraction form. A second review author (ES) spot‐checked study characteristics for accuracy against the trial report. </p> </section> <section id="CD003336-sec-0031"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (ES, MK) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD003336-bbs2-0030" title="HigginsJPT , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We resolved any disagreements by discussion or by involving another author (GL). We assessed the risk of bias according to the following domains. </p> <p> <ol id="CD003336-list-0005"> <li> <p>Random sequence generation</p> </li> <li> <p>Allocation concealment</p> </li> <li> <p>Blinding of participants and personnel</p> </li> <li> <p>Blinding of outcome assessment</p> </li> <li> <p>Incomplete outcome data</p> </li> <li> <p>Selective outcome reporting</p> </li> <li> <p>Other bias</p> </li> </ol> </p> <p>We classified each potential source of bias as high, low, or unclear, and provided a quote from the study report, together with a justification for our judgment in the risk of bias table. We summarised the risk of bias judgements across different studies for each of the domains listed. When information on risk of bias was related to unpublished data or correspondence with a trialist, we noted this in the risk of bias table. </p> <p>When considering treatment effects, we took into account the risk of bias for the studies that contributed to that outcome. </p> </section> <section id="CD003336-sec-0032"> <h4 class="title">Measures of treatment effect</h4> <p>We analysed dichotomous data as Peto odds ratio. We did not include any continuous outcomes in the review. </p> <p>We narratively described skewed data reported as medians and interquartile ranges.</p> </section> <section id="CD003336-sec-0033"> <h4 class="title">Unit of analysis issues</h4> <p>The reviews included RCTs with parallel design. We did not include trials with multiple time points, or trials with more than two arms. </p> </section> <section id="CD003336-sec-0034"> <h4 class="title">Dealing with missing data</h4> <p>We contacted investigators or study sponsors, to verify key study characteristics and obtain missing numerical outcome data, where possible (e.g. when a study was identified as an abstract only). When this was not possible, and we thought the missing data might introduce serious bias, we explored the impact of including such studies in the overall assessment of results with a sensitivity analysis. </p> </section> <section id="CD003336-sec-0035"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects, and the degree of overlap between confidence intervals. We used the I² statistic to measure heterogeneity among the trials in each analysis, but acknowledged that there was substantial uncertainty in the value of I² when there was only a small number of studies. We also considered the P value from the Chi² test. If we identified substantial heterogeneity, we have reported it. However, we did not explored possible causes by prespecified subgroup analysis due to the small amount of studies. We defined substantial heterogeneity using a threshold I² of 50% or above. </p> </section> <section id="CD003336-sec-0036"> <h4 class="title">Assessment of reporting biases</h4> <p>If we were able to pool more than 10 trials, we would have created and examined a funnel plot to explore possible small study biases for the primary outcomes. </p> </section> <section id="CD003336-sec-0037"> <h4 class="title">Data synthesis</h4> <p>We undertook meta‐analyses only when this was meaningful, i.e. if the treatments, participants, and the underlying clinical question were similar enough for pooling to make sense. </p> <p>We used a fixed‐effect model, as the previous updates of the analysis indicated a relatively small number of eligible trials, and we assumed the same intervention effect. </p> </section> <section id="CD003336-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We planned to carry out the following subgroup analyses:</p> <p> <ol id="CD003336-list-0006"> <li> <p>Ischaemic versus non‐ischaemic aetiology of HF</p> </li> <li> <p>Preserved versus reduced EF (e.g. left ventricular EF ≥ 50% versus &lt; 40%)</p> </li> </ol> </p> <p>for the following outcomes:</p> <p> <ol id="CD003336-list-0007"> <li> <p>All‐cause death</p> </li> <li> <p>Stroke</p> </li> </ol> </p> <p>Due to the small number of included studies, we did not conduct these planned subgroup analyses. </p> </section> <section id="CD003336-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to carry out the following sensitivity analyses, to test whether key methodological factors or decisions affected the main result. </p> <p> <ol id="CD003336-list-0008"> <li> <p>Only including studies with a low risk of bias (e.g. low risk in at least four domains)</p> </li> <li> <p>If we found substantial heterogeneity, comparing results from a random‐effects model with those from the planned fixed‐effect model </p> </li> </ol> </p> <p>Due to the small number of included studies, we did not conduct these planned sensitivity analyses. </p> </section> <section id="CD003336-sec-0040"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We created a summary of findings table using the following outcomes: all‐cause death, stroke, and major bleeding events. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of a body of evidence as it related to the studies that contributed data to the meta‐analyses for each important outcome. We used methods and recommendations described in Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> and GRADEpro software (<a href="./references#CD003336-bbs2-0028" title="McMaster University (developed by Evidence Prime)GRADEpro GDT. Version accessed in November 2020. Hamilton (ON): McMaster University (developed by Evidence Prime). Available at gradepro.org.">GRADEpro GDT</a>; <a href="./references#CD003336-bbs2-0045" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing summary of findings tables and grading the certainty of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.1 (updated September 2020). Cochrane, 2020. Available from www.training.cochrane.org/handbook.">Schünemann 2020</a>). We created two summary of findings tables for the different comparisons: warfarin versus control, and rivaroxaban versus placebo. We justified all decisions to downgrade the quality of studies in footnotes, and made comments to aid the reader's understanding of the review, where necessary. </p> <p>Two review authors (ES, MK) independently made judgements about the quality of the evidence. They resolved disagreements through discussion, or by involving a third review author (GL). They justified and documented the judgements, incorporating them into the reports of the results for each outcome. </p> <p>We extracted study data, formatted our comparisons in data tables, and prepared a summary of findings table before writing the results and conclusions of our review. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD003336-sec-0041" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD003336-sec-0041"></div> <section id="CD003336-sec-0042"> <h3 class="title">Description of studies</h3> <section id="CD003336-sec-0043"> <h4 class="title">Results of the search</h4> <p>The previous searches in 2001 and 2005 identified 1100 records, four studies (four records) of which met the inclusion criteria. </p> <p>The updated search in 2010 identified 1219 records, one of which was previously identified as an ongoing study and was included (<a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>); and another of which was previously identified as an ongoing study and was excluded (<a href="./references#CD003336-bbs2-0018" title="MessieBM , CollinsJF , AmmonSE , ArmstrongPW , ClelandJG , EzekowitzM , et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation Mar 31;119(12):1616-24. ">WATCH 2009</a>). One study remained ongoing (<a href="./references#CD003336-bbs2-0017" title="HommaS , ThompsonJL , PullicinoPM , LevinB , FreudenbergerRS , TeerlinkJR , et al, the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine2012;366:1859-69. ">WARCEF 2012</a>). </p> <p>The updated search in 2013 identified 1460 new records, none of which we included.</p> <p>The updated search in 2020 identified 2767 records. We removed 489 duplicates, and screened 2278 records. We assessed 49 records for eligibility, and excluded 47 records with reasons: 31 studies included the wrong population, and 16 studies were not randomised. We described only the studies that mostly narrowly missed inclusion. We included one new RCT (with two references (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>); see <a href="#CD003336-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD003336-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="PRISMA flowchart" data-id="CD003336-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA flowchart</p> </div> </div> </div> <p>We identified three small prospective controlled studies of warfarin in HF in the previous search, but they were over 50 years old, with methods not considered reliable by modern standards, so we excluded them (<a href="./references#CD003336-bbs2-0004" title="AndersonGM , HullE . The effects of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. American Heart Journal1950;39:697-702. ">Anderson 1950</a>; <a href="./references#CD003336-bbs2-0008" title="GriffithGC , StragnellR , LevinsonDC , MooreFJ , WareAG . A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Annals of Internal Medicine1952;37:867-87. ">Griffith 1952</a>; <a href="./references#CD003336-bbs2-0009" title="HarveyWP , FinchCA . Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. New England Journal of Medicine1950;242:208-11. ">Harvey 1950</a>).   </p> <p>In total, this review includes three studies (see <a href="./references#CD003336-sec-0112" title="">Characteristics of included studies</a>). </p> </section> <section id="CD003336-sec-0044"> <h4 class="title">Included studies</h4> <p>We included three studies, with a total of 5498 participants (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>; <a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>; <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>). </p> <p><a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a> was a pilot study of 279 participants with heart failure (HF) randomised to anticoagulation with warfarin (89 participants; target international normalized ratio (INR) 2.5); aspirin (300 mg; 91 participants); or no antithrombotic therapy (99 participants). This was an open label trial design and therefore, performance bias could not be excluded (see risk of bias table). </p> <p><a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a> was a study of 115 participants with ischaemic heart disease randomised to anticoagulation (target INR 2.0 to 3.0) or aspirin, and a group of 82 participants randomised to anticoagulation (target INR 2.0 to 3.0; 38 participants) or placebo (44 participants). This was a double‐blind trial with an independent data and safety monitoring committee. </p> <p><a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a> was a study of 5022 participants with HF and coronary artery disease randomised to rivaroxaban (2507 participants) or placebo (2515 participants). This was a double‐blind placebo‐controlled trial. Participants were randomised using an interactive web‐response system and permuted blocks of four. An independent data and safety monitoring committee had access to unblinded data during the trial and was responsible for the safety of the enrolled individuals. </p> <p>Two studies exclusively or predominantly recruited from European countries (<a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>; <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>). One study was conducted in Europe, Asia, North and Latin America, and Africa (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>). One trial reported receiving relevant industry sponsorship (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>). </p> </section> <section id="CD003336-sec-0045"> <h4 class="title">Excluded studies</h4> <p>We excluded 16 studies, four of which were observational studies (<a href="./references#CD003336-bbs2-0006" title="EchemannM , AllaF , BrianconS , JuilliereY , VirionJM , MertesPM , et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) [Epidemiologie de l'insuffisance cardiaque avancee en Lorraine]. European Journal of Heart Failure2002;4(5):647-54. ">EPICAL 2002</a>; <a href="./references#CD003336-bbs2-0007" title="FusterV , GershBJ , GiulianiER , TajikAJ , BradenburgRO , FryeRL . The natural history of idiopathic dilated cardiomyopathy. American Journal of Cardiology1981;47:525-31. ">Fuster 1981</a>; <a href="./references#CD003336-bbs2-0010" title="KyrlePA , KorningerC , GossingerH , GlogarD , LechnerK , NiessnerH , et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thrombosis and Haemostasis1985;54:521-3. ">Kyrle 1985</a>; <a href="./references#CD003336-bbs2-0011" title="NattersonPD , StevensonWG , SaxonLA , MiddlekauffHR , StevensonLW . Low risk of arterial embolization in outpatients awaiting cardiac transplantation. Circulation1993;88(Suppl I):603. ">Natterson 1993</a>). We provided the adverse event information in the discussion. See <a href="./references#CD003336-sec-0113" title="">Characteristics of excluded studies</a> for details. </p> <p><a href="./references#CD003336-bbs2-0007" title="FusterV , GershBJ , GiulianiER , TajikAJ , BradenburgRO , FryeRL . The natural history of idiopathic dilated cardiomyopathy. American Journal of Cardiology1981;47:525-31. ">Fuster 1981</a> was a retrospective study of 104 participants with idiopathic dilated cardiomyopathy followed up for a total of 725 person‐years. <a href="./references#CD003336-bbs2-0010" title="KyrlePA , KorningerC , GossingerH , GlogarD , LechnerK , NiessnerH , et al. Prevention of arterial and pulmonary embolism by oral anticoagulants in patients with dilated cardiomyopathy. Thrombosis and Haemostasis1985;54:521-3. ">Kyrle 1985</a> was a study of 38 participants with non‐ischaemic cardiomyopathy followed for a total of 72 person‐years. <a href="./references#CD003336-bbs2-0011" title="NattersonPD , StevensonWG , SaxonLA , MiddlekauffHR , StevensonLW . Low risk of arterial embolization in outpatients awaiting cardiac transplantation. Circulation1993;88(Suppl I):603. ">Natterson 1993</a> was a more recent study of 224 participants awaiting cardiac transplantation. <a href="./references#CD003336-bbs2-0006" title="EchemannM , AllaF , BrianconS , JuilliereY , VirionJM , MertesPM , et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) [Epidemiologie de l'insuffisance cardiaque avancee en Lorraine]. European Journal of Heart Failure2002;4(5):647-54. ">EPICAL 2002</a> was a study of 417 participants with an average follow‐up period of five years. <a href="./references#CD003336-bbs2-0006" title="EchemannM , AllaF , BrianconS , JuilliereY , VirionJM , MertesPM , et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) [Epidemiologie de l'insuffisance cardiaque avancee en Lorraine]. European Journal of Heart Failure2002;4(5):647-54. ">EPICAL 2002</a> was eventually excluded as 24% had concomitant AF. Only survival was reported and event rates were not reported separately for the sinus rhythm group or those treated with aspirin, warfarin or no therapy. Aspirin was used in 31% of participants, warfarin in 28% of participants, and warfarin plus aspirin in 2% of participants. Participants given any antithrombotic treatment compared to none had a better survival at five years (40.4% versus 31%, P = 0.01). </p> <p>One case series, conducted over 50 years ago in an heterogeneous HF population (N = 61), was excluded but it did report that the prevalence of thromboembolism on dicumarol (6.5%) was lower compared to previously published reports (22%) (<a href="./references#CD003336-bbs2-0019" title="WishartJH , ChapmanCB . Dicumarol therapy in congestive heart failure. New England Journal of Medicine1948;239:701-4. ">Wishart 1948</a>). </p> <p>Five publications from RCTs were excluded because the participants in the analyses were not randomised to anticoagulant or control in the original study (<a href="./references#CD003336-bbs2-0005" title="CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New England Journal of Medicine1987;316(23):1429-35. [DOI: 10.1056/NEJM198706043162301] [PMID: 2883575]">CONSENSUS 1987</a>; <a href="./references#CD003336-bbs2-0012" title="FalkR , PollackA , TandonPK , PackerM . The effect of warfarin on prevalence of stroke in severe heart failure. Journal of the American College of Cardiology1993;21(Suppl A):218A. ">PROMISE 1993</a>; <a href="./references#CD003336-bbs2-0013" title="LohE , SuttonMS , WunCC , RouleauJL , FlakerGC , GottliebSS , et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. New England Journal of Medicine1997;336:251-7. ">SAVE 1997</a>; <a href="./references#CD003336-bbs2-0014" title="Al-KhadraAS , SalemDN , RandWM , UdelsonJE , SmithJJ , KonstamMA . Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology1998;31(4):749-53. ">SOLVD 1998</a>; <a href="./references#CD003336-bbs2-0015" title="DunkmanWB , JohnsonGR , CarsonPE , BhatG , FarrellL , CohnJN , the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation1993;87(Suppl VI):94-101. ">V‐HeFT 1993</a>). The analyses were post hoc analyses of participants treated with oral anticoagulation at the discretion of the investigators. The <a href="./references#CD003336-bbs2-0015" title="DunkmanWB , JohnsonGR , CarsonPE , BhatG , FarrellL , CohnJN , the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation1993;87(Suppl VI):94-101. ">V‐HeFT 1993</a> trials included participants with symptomatic HF with radiological, echocardiographic or radionuclide evidence of left ventricular systolic dysfunction (<a href="./references#CD003336-bbs2-0015" title="DunkmanWB , JohnsonGR , CarsonPE , BhatG , FarrellL , CohnJN , the V-HeFT VA Cooperative Studies Group. Incidence of thromboembolic events in congestive heart failure. Circulation1993;87(Suppl VI):94-101. ">V‐HeFT 1993</a>). The <a href="./references#CD003336-bbs2-0014" title="Al-KhadraAS , SalemDN , RandWM , UdelsonJE , SmithJJ , KonstamMA . Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology1998;31(4):749-53. ">SOLVD 1998</a> trials included participants with left ventricular systolic dysfunction, defined as a left ventricular EF of 35% or more, who were symptomatic and enrolled into the treatment trial or asymptomatic and enrolled into the prevention trial (<a href="./references#CD003336-bbs2-0014" title="Al-KhadraAS , SalemDN , RandWM , UdelsonJE , SmithJJ , KonstamMA . Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. Journal of the American College of Cardiology1998;31(4):749-53. ">SOLVD 1998</a>). Limited information from a retrospective analysis of one trial has been presented in abstract form only (<a href="./references#CD003336-bbs2-0012" title="FalkR , PollackA , TandonPK , PackerM . The effect of warfarin on prevalence of stroke in severe heart failure. Journal of the American College of Cardiology1993;21(Suppl A):218A. ">PROMISE 1993</a>). The <a href="./references#CD003336-bbs2-0013" title="LohE , SuttonMS , WunCC , RouleauJL , FlakerGC , GottliebSS , et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. New England Journal of Medicine1997;336:251-7. ">SAVE 1997</a> study included participants post‐MI with a left ventricular EF of 40% or more and no overt HF, that is, asymptomatic participants (<a href="./references#CD003336-bbs2-0013" title="LohE , SuttonMS , WunCC , RouleauJL , FlakerGC , GottliebSS , et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. New England Journal of Medicine1997;336:251-7. ">SAVE 1997</a>). One further study was a cohort study of people attending an outpatient anticoagulation clinic for a variety of co‐morbidities (<a href="./references#CD003336-bbs2-0016" title="VisserLE , BleuminkGS , TrienekensPH , VultoAG , HofmanA , StrickerBH . The risk of overanticoagulation in patients with heart failure on coumarin anticoagulants. British Journal of Haematology2004;127(1):85-9. ">Visser 2004</a>). Two studies were excluded as the control group received aspirin or clopidogrel, but not placebo (<a href="./references#CD003336-bbs2-0017" title="HommaS , ThompsonJL , PullicinoPM , LevinB , FreudenbergerRS , TeerlinkJR , et al, the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine2012;366:1859-69. ">WARCEF 2012</a>; <a href="./references#CD003336-bbs2-0018" title="MessieBM , CollinsJF , AmmonSE , ArmstrongPW , ClelandJG , EzekowitzM , et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation Mar 31;119(12):1616-24. ">WATCH 2009</a>). </p> <p>The earlier prospective controlled studies were performed over 50 years ago in hospitalised people with a high prevalence of rheumatic heart disease and AF (<a href="./references#CD003336-bbs2-0004" title="AndersonGM , HullE . The effects of dicumarol upon the mortality and incidence of thromboembolic complications in congestive heart failure. American Heart Journal1950;39:697-702. ">Anderson 1950</a>; <a href="./references#CD003336-bbs2-0008" title="GriffithGC , StragnellR , LevinsonDC , MooreFJ , WareAG . A study of the beneficial effects of anticoagulant therapy in congestive heart failure. Annals of Internal Medicine1952;37:867-87. ">Griffith 1952</a>; <a href="./references#CD003336-bbs2-0009" title="HarveyWP , FinchCA . Dicumarol prophylaxis of thromboembolic disease in congestive heart failure. New England Journal of Medicine1950;242:208-11. ">Harvey 1950</a>). Although described as 'randomised', the trial methodologies in these studies are more properly described as quasi‐randomised and cannot be seen as entirely reliable by modern standards. Moreover, routine standards of care over 50 years ago were different than current standards of care.  </p> </section> </section> <section id="CD003336-sec-0046"> <h3 class="title">Risk of bias in included studies</h3> <p>Risk of bias is shown in <a href="#CD003336-fig-0002">Figure 2</a> and <a href="#CD003336-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD003336-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003336-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <div class="figure" id="CD003336-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003336-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD003336-sec-0047"> <h4 class="title">Allocation</h4> <p>The three studies were at low risk of selection bias, because they were designed as RCTs. In <a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>, computerised randomisation was conducted by fax or by phone to the Coordinating Centre. In <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>, participants were randomised according to prospectively constructed blocks of random numbers. <a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a> study, participants were randomly assigned to receive rivaroxaban or placebo in a ratio 1:1. Central randomisation was based on a computer‐generated randomisation schedule. Participants were randomised using an interactive Web response system and permuted blocks of four. Randomisation was stratified by country. The investigator was not informed about randomisation codes. The codes were maintained within the system, which had the functionality to allow the investigator to break the blind for an individual subject.  </p> </section> <section id="CD003336-sec-0048"> <h4 class="title">Blinding</h4> <p>We assessed one study at high risk of performance bias (open label trial), but low risk of detection bias (blinded endpoint design (<a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>)). </p> <p>Another study was a double‐blind study, which we judged at unclear risk of performance bias (<a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>). The investigator‐supervisor was blinded to the study and placebo tablets were given daily or according to sham adjustment. The dose of the drug was administered to the participants by second physician. In the placebo group, the supervisor recommended the dose according to sham results. This study was monitored by an independent data and safety monitoring committee. The occurrence of clinical endpoints was recorded (unclear risk of detection bias). </p> <p>We judged the third study at a low risk of performance bias (double‐blind study) and a low risk of detection bias (outcomes were confirmed by investigators using an extensive, dedicated case‐report form, with source‐data verification by the sponsor's clinical operations team (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>)). However, events were not centrally adjudicated. </p> </section> <section id="CD003336-sec-0049"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed two studies at unclear risk of attrition bias (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>; <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>). In <a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>, data on vital status were available for 5013 participants (99.8%). <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a> did not provide data on participants who were lost to follow‐up. We assessed one study at a low risk of attrition bias, since all participants were included in the follow‐up analysis (<a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>). All participants were included in the follow‐up analysis and an independent data committee performed interim analyses to determine whether continuation of any of the treatment arms might be detrimental to the participants. </p> </section> <section id="CD003336-sec-0050"> <h4 class="title">Selective reporting</h4> <p>We judged all three studies at a low risk of reporting bias, since they all reported on predefined primary and secondary outcomes. The results of the above mentioned studies showed that treatment had no effect on outcome, and therefore were negative studies.  </p> </section> <section id="CD003336-sec-0051"> <h4 class="title">Other potential sources of bias</h4> <p>In one study, cross‐over rates were 25% at 12 months what might have affected the certainty of the results or the risk of bias (<a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>). </p> </section> </section> <section id="CD003336-sec-0052"> <h3 class="title" id="CD003336-sec-0052">Effects of interventions</h3> <p>See: <a href="./full#CD003336-tbl-0001"><b>Summary of findings 1</b> Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm</a>; <a href="./full#CD003336-tbl-0002"><b>Summary of findings 2</b> Rivaroxaban compared to placebo in people with heart failure in sinus rhythm</a> </p> <section id="CD003336-sec-0053"> <h4 class="title">Warfarin compared to control</h4> <p>Two studies contributed data for this comparison. In the <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a> trial, 99 participants received no treatment compared to 89 participants who received warfarin; they were followed for a mean of 27 months. The <a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a> study did not achieve the target recruitment of 6000 participants. Eighty‐two participants with idiopathic dilated cardiomyopathy were randomised to receive either warfarin or placebo.  </p> <section id="CD003336-sec-0054"> <h5 class="title">Primary outcomes</h5> <section id="CD003336-sec-0055"> <h6 class="title">All‐cause death</h6> <p>Both studies reported all‐cause death. The evidence is uncertain if warfarin has any effect on all‐cause death compared to no treatment or placebo, because the certainty of the evidence is low, and the 95% confidence interval (CI) is consistent with possible benefit and possible harm (odds ratio (OR) 0.66, 95% CI 0.36 to 1.18; 2 studies, 324 participants; low‐certainty evidence; <a href="./references#CD003336-fig-0004" title="">Analysis 1.1</a>). </p> </section> <section id="CD003336-sec-0056"> <h6 class="title">Stroke</h6> <p>None of the studies reported stroke as an individual outcome.</p> </section> </section> <section id="CD003336-sec-0057"> <h5 class="title">Secondary outcomes</h5> <section id="CD003336-sec-0058"> <h6 class="title">Cardiovascular death (including sudden death)</h6> <p>The evidence is uncertain if warfarin has any effect on cardiovascular deaths (OR 0.98, 95% CI 0.58 to 1.65; 2 studies, 324 participants; <a href="./references#CD003336-fig-0005" title="">Analysis 1.2</a>). </p> </section> <section id="CD003336-sec-0059"> <h6 class="title">Myocardial infarction (MI)</h6> <p>The evidence is uncertain if warfarin has any effect on the risk of MI (OR 0.64, 95% CI 0.20 to 2.08; 2 studies, 324 participants; <a href="./references#CD003336-fig-0006" title="">Analysis 1.3</a>).  </p> </section> <section id="CD003336-sec-0060"> <h6 class="title">Pulmonary embolism</h6> <p>None of the studies reported data on pulmonary embolism. </p> </section> <section id="CD003336-sec-0061"> <h6 class="title">Peripheral arterial embolism</h6> <p>None of the studies reported data on peripheral arterial embolism. </p> </section> <section id="CD003336-sec-0062"> <h6 class="title">Major bleeding events</h6> <p>Both studies reported major bleeding events. Warfarin may increase the risk of major bleeding events (OR 5.98, 95% CI 1.71 to 20.93; 2 studies, 324 participants; low‐certainty evidence; NNTH 17, <a href="./references#CD003336-fig-0007" title="">Analysis 1.4</a>). </p> </section> </section> </section> <section id="CD003336-sec-0063"> <h4 class="title">Rivaroxaban compared to control</h4> <p>In the <a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a> study, 2507 participants were randomised to receive rivaroxaban, and 2515 participants were randomised to receive placebo; they were followed for a median duration of 21.1 months.  </p> <section id="CD003336-sec-0064"> <h5 class="title">Primary outcomes</h5> <section id="CD003336-sec-0065"> <h6 class="title">All‐cause death</h6> <p>Rivaroxaban makes little to no difference to the risk of all‐cause death (OR 0.99, 95% CI 0.87 to 1.13; 1 study, 5022 participants; high‐certainty evidence; <a href="./references#CD003336-fig-0008" title="">Analysis 2.1</a>). </p> </section> <section id="CD003336-sec-0066"> <h6 class="title">Stroke</h6> <p>Rivaroxaban probably reduces the risk of stroke (OR 0.67, 95% CI 0.47 to 0.95; NNTB 101, 1 study, 5022 participants; moderate‐certainty evidence; <a href="./references#CD003336-fig-0010" title="">Analysis 2.3</a>). </p> </section> </section> <section id="CD003336-sec-0067"> <h5 class="title">Secondary outcomes</h5> <section id="CD003336-sec-0068"> <h6 class="title">Cardiovascular death (including sudden death)</h6> <p>Rivaroxaban may make little to no difference to the risk of cardiovascular death (OR 1.00, 95% CI 0.86 to 1.15; 1 study, 5022 participants; <a href="./references#CD003336-fig-0009" title="">Analysis 2.2</a>). </p> </section> <section id="CD003336-sec-0069"> <h6 class="title">Myocardial infarction (MI)</h6> <p>The evidence is uncertain if rivaroxaban has any effect on the the risk of MI (OR 0.83, 95% CI 0.63 to 1.09; 1 study, 5022 participants; <a href="./references#CD003336-fig-0011" title="">Analysis 2.4</a>).  </p> </section> <section id="CD003336-sec-0070"> <h6 class="title">Pulmonary embolism</h6> <p>The evidence is uncertain if rivaroxaban has any effect on the risk of symptomatic pulmonary embolism (OR 1.23, 95% CI 0.51 to 2.97; 1 study, 5022 participants; <a href="./references#CD003336-fig-0012" title="">Analysis 2.5</a>). </p> </section> <section id="CD003336-sec-0071"> <h6 class="title">Peripheral arterial embolism</h6> <p>The study did not report data on peripheral arterial embolism.</p> </section> <section id="CD003336-sec-0072"> <h6 class="title">Major bleeding events</h6> <p>Rivaroxaban probably increases the risk of major bleeding events compared to no treatment (OR 1.65, 95% CI 1.17 to 2.33; 1 study, NNTH 79; 5008 participants; moderate‐certainty evidence; <a href="./references#CD003336-fig-0013" title="">Analysis 2.6</a>). </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD003336-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD003336-sec-0073"></div> <section id="CD003336-sec-0074"> <h3 class="title" id="CD003336-sec-0074">Summary of main results</h3> <p>We included three prospective randomised controlled studies (RCT) of oral anticoagulation in 5498 people with heart failure (HF) in this review (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>; <a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>; <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>). </p> <p>The evidence is uncertain if warfarin has any effect on all‐cause death compared to placebo or no treatment. Warfarin may increase the risk of major bleeding events. </p> <p>There is evidence of no difference for rivaroxaban's effect on all‐cause death compared to placebo. Rivaroxaban compared to placebo probably reduces the risk of stroke, but increases the risk of major bleedings events. </p> <p>Therefore, these three studies do not support the routine use of oral anticoagulation therapy for people with HF in sinus rhythm. </p> </section> <section id="CD003336-sec-0075"> <h3 class="title" id="CD003336-sec-0075">Overall completeness and applicability of evidence</h3> <p>The included studies had some limitations in overall completeness and applicability of evidence. <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a> was not blinded and was underpowered to provide an answer to our review question. Unfortunately, cross‐over rates were 25% at 12 months what might have affected the certainty of the results or the risk of bias. In <a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>, participants were representative of those in clinical population. In <a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>, the events were not centrally adjudicated, and thus, the risk of misclassification of causes of hospitalisation and death exist. Moreover, the rate of discontinuing the trial regimen was relatively high (16.3 in the rivaroxaban group, and 13.6 per 100 person‐years in the placebo group).  </p> </section> <section id="CD003336-sec-0076"> <h3 class="title" id="CD003336-sec-0076">Quality of the evidence</h3> <p>The three studies were RCTs, but contributed to the quality of the evidence with some limitations.  </p> <p>For warfarin versus placebo or no treatment, we downgraded all‐cause death by two levels, once for imprecision, since the 95% confidence interval crossed the line of no effect, and once for inconsistency, due to high heterogeneity (80%) across studies. We downgraded major bleeding events twice for imprecision, due to the small sample size and low event rate.  </p> <p> We downgraded the single trial of rivaroxaban included in the review  by one level for imprecision for stroke and major bleeding events, since both of these outcomes have very low event rates (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>).  </p> </section> <section id="CD003336-sec-0077"> <h3 class="title" id="CD003336-sec-0077">Potential biases in the review process</h3> <p>The process of updating the review was done independently by two authors (ES and MK). The potential bias in the review process might be associated with selection of outcomes. For example, we did not assess all‐cause hospitalisations or cardiovascular hospitalisations. Moreover, cross‐over rates in the studies seem to be undesirable when testing therapeutic agents. </p> </section> <section id="CD003336-sec-0078"> <h3 class="title" id="CD003336-sec-0078">Agreements and disagreements with other studies or reviews</h3> <p>The available, current evidence does not support the routine use of oral anticoagulation over no therapy or placebo in people with HF and sinus rhythm. <a href="./references#CD003336-bbs2-0022" title="BeggsSA , RørthR , GardnerRS , McMurrayJJ . Anticoagulation therapy in heart failure and sinus rhythm: a systematic review and meta-analysis. Heart 2019 Sep;105(17):1325-34.">Beggs 2019</a> included five studies in their systematic review and meta‐analysis (<a href="./references#CD003336-bbs2-0001" title="MehraMR , VaduganathanM , FuM , FerreiraJP , AnkerSD , ClelandJG , et al. A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial. European Heart Journal November 2019;40(42):3593–602. ZannadF , AnkerSD , ByraWM , ClelandJGF , FuM , GheorghiadeM , et al. Rivaroxaban in patients with heart failure, sinus rhythm, and coronary disease. New England Journal of Medicine2018;379:1332-42. ">COMMANDER HF 2018</a>; <a href="./references#CD003336-bbs2-0002" title="CokkinosDV , HaralabopoulosGC , KostisJB , ToutouzasPK . Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. European Journal of Heart Failure2006;8:428-32. ">HELAS 2006</a>; <a href="./references#CD003336-bbs2-0017" title="HommaS , ThompsonJL , PullicinoPM , LevinB , FreudenbergerRS , TeerlinkJR , et al, the WARCEF Investigators. Warfarin and aspirin in patients with heart failure and sinus rhythm. New England Journal of Medicine2012;366:1859-69. ">WARCEF 2012</a>; <a href="./references#CD003336-bbs2-0003" title="ClelandJG , FindlayI , JafriS , SuttonG , FalkR , BulpittC , et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. American Heart Journal2004;148:157-64. ">WASH 2004</a>; <a href="./references#CD003336-bbs2-0018" title="MessieBM , CollinsJF , AmmonSE , ArmstrongPW , ClelandJG , EzekowitzM , et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation Mar 31;119(12):1616-24. ">WATCH 2009</a>). They found that oral anticoagulant therapy did not reduce all‐cause mortality, hospitalisation due to HF, or non‐fatal myocardial infarction (MI) when compared with control therapy. Oral anticoagulation reduced the rate of non‐fatal stroke and increased the incidence of major haemorrhages. The authors concluded that thrombosis or embolism did not play an important role in the morbidity and mortality associated with heart failure with reduced ejection fraction (HFrEF), with the exception of stroke‐related morbidity.  </p> <p><a href="./references#CD003336-bbs2-0006" title="EchemannM , AllaF , BrianconS , JuilliereY , VirionJM , MertesPM , et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) [Epidemiologie de l'insuffisance cardiaque avancee en Lorraine]. European Journal of Heart Failure2002;4(5):647-54. ">EPICAL 2002</a>, an observational study, found that of the 417 participants with a mean left ventricular ejection fraction of 22%, New York Heart Association (NYHA) class III or IV, 45% with ischaemic origin demonstrated a significant reduction in thromboembolic events. Therefore, it is possible that the efficacy of oral anticoagulation may differ according to the cause of HF, as people with idiopathic cardiomyopathy may have a greater risk of cardiogenic thromboembolism whilst those with atherosclerosis are also at risk of other vascular events including in situ coronary artery thrombosis. <a href="./references#CD003336-bbs2-0006" title="EchemannM , AllaF , BrianconS , JuilliereY , VirionJM , MertesPM , et al. Antithrombotic therapy is associated with better survival in patients with severe heart failure and left ventricular systolic dysfunction (EPICAL study) [Epidemiologie de l'insuffisance cardiaque avancee en Lorraine]. European Journal of Heart Failure2002;4(5):647-54. ">EPICAL 2002</a> suggested that anticoagulation with warfarin was beneficial in people with severe HF, in particular those with NYHA class III or IV. </p> <p>In conclusion, the present (limited) data do not support the routine use in people with HF who remain in sinus rhythm. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD003336-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-FIG-01" target="_blank"><b></b></a></p> </div><img alt="PRISMA flowchart" data-id="CD003336-fig-0001" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>PRISMA flowchart</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD003336-fig-0002" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD003336-fig-0003" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Warfarin versus control, Outcome 1: All‐cause death" data-id="CD003336-fig-0004" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Warfarin versus control, Outcome 1: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Warfarin versus control, Outcome 2: Cardiovascular death (including sudden death)" data-id="CD003336-fig-0005" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Warfarin versus control, Outcome 2: Cardiovascular death (including sudden death) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Warfarin versus control, Outcome 3: Myocardial infarction" data-id="CD003336-fig-0006" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Warfarin versus control, Outcome 3: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Warfarin versus control, Outcome 4: Major bleeding events" data-id="CD003336-fig-0007" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: Warfarin versus control, Outcome 4: Major bleeding events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Rivaroxaban versus placebo, Outcome 1: All‐cause death" data-id="CD003336-fig-0008" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Rivaroxaban versus placebo, Outcome 1: All‐cause death</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Rivaroxaban versus placebo, Outcome 2: Cardiovascular death (including sudden death)" data-id="CD003336-fig-0009" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Rivaroxaban versus placebo, Outcome 2: Cardiovascular death (including sudden death) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Rivaroxaban versus placebo, Outcome 3: Stroke" data-id="CD003336-fig-0010" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Rivaroxaban versus placebo, Outcome 3: Stroke</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Rivaroxaban versus placebo, Outcome 4: Myocardial infarction" data-id="CD003336-fig-0011" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: Rivaroxaban versus placebo, Outcome 4: Myocardial infarction</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Rivaroxaban versus placebo, Outcome 5: Pulmonary embolism" data-id="CD003336-fig-0012" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: Rivaroxaban versus placebo, Outcome 5: Pulmonary embolism</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD003336-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/urn:x-wiley:14651858:media:CD003336:CD003336-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Rivaroxaban versus placebo, Outcome 6: Major bleeding events" data-id="CD003336-fig-0013" src="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_t/tCD003336-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: Rivaroxaban versus placebo, Outcome 6: Major bleeding events</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/media/CDSR/CD003336/image_n/nCD003336-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD003336-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm</span></div> <tbody> <tr class="separated"> <th align="left" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with heart failure in sinus rhythm<br/><b>Setting:</b> outpatient clinics<br/><b>Intervention:</b> warfarin<br/><b>Comparison:</b> placebo or no treatment </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo or no treatment</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with warfarin</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>203 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000<br/>(84 to 231) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.66<br/>(0.36 to 1.18) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low certainty<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p>Stroke was not reported as an individual outcome.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events<sup>c</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>0/143</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>11/181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 5.98<br/>(1.71 to 20.93) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>324<br/>(2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low certainty<sup>b</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0 per 1000 in the control arm for major bleeding events. It is not based on the estimated relative effect. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>OR:</b> odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded twice – once for imprecision, and once for inconsistency due to high heterogeneity<br/><sup>b</sup>Downgraded twice for imprecision, due to the small sample size and low event rate </p> <p><sup>c</sup>A major bleeding event is defined by the International Society on Thrombosis and Haemostasis as overt bleeding associated with a decrease in haemoglobin level of at least 2 g/dL, transfusion of two or more units of packed red cells or whole blood, bleeding in a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, or retroperitoneal), or a fatal outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Warfarin compared to placebo or no treatment in people with chronic heart failure in sinus rhythm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD003336-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rivaroxaban compared to placebo in people with heart failure in sinus rhythm</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Rivaroxaban compared to placebo in people with heart failure in sinus rhythm</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with heart failure in sinus rhythm<br/><b>Setting:</b> hospital or outpatient clinic<br/><b>Intervention:</b> rivaroxaban<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="center" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with rivaroxaban</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>All‐cause death</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>227 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>225 per 1000<br/>(204 to 249) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.99<br/>(0.87 to 1.13) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5022<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High certainty</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Stroke</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>30 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000<br/>(14 to 29) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 0.67<br/>(0.47 to 0.95) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5022<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate certainty<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Major bleeding events<sup>b</sup> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>20 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/>(23 to 45) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>OR 1.65<br/>(1.17 to 2.33) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5008<br/>(1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate certainty<sup>a</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> Confidence interval; <b>OR:</b> Odds ratio; </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty.</b> We are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty.</b> We are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty.</b> Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty.</b> We have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded for imprecision, due to very low event rates.<br/><sup>b</sup>A major bleeding event is defined by the International Society on Thrombosis and Haemostasis as overt bleeding associated with a decrease in haemoglobin level of at least 2 g/dL, transfusion of two or more units of packed red cells or whole blood, bleeding in a critical site (intracranial, intraspinal, intraocular, pericardial, intraarticular, intramuscular with compartment syndrome, or retroperitoneal), or a fatal outcome. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Rivaroxaban compared to placebo in people with heart failure in sinus rhythm</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/full#CD003336-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003336-tbl-0003"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Warfarin versus control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.66 [0.36, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Cardiovascular death (including sudden death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.58, 1.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [0.20, 2.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 Major bleeding events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>324</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.98 [1.71, 20.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Warfarin versus control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD003336-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rivaroxaban versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 All‐cause death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Cardiovascular death (including sudden death) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Stroke <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 Myocardial infarction <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Pulmonary embolism <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 Major bleeding events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Peto Odds Ratio (Peto, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Rivaroxaban versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD003336.pub4/references#CD003336-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD003336.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD003336-note-0013">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD003336-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD003336-note-0011">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD003336-note-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD003336-note-0007">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD003336-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD003336-note-0012">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD003336-note-0006">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD003336-note-0005">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003336\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003336\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003336\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD003336\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD003336\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=Xx9QLps0&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003336.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD003336.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD003336.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD003336.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD003336.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740715495955"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003336.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740715495959"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD003336.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d8884c8359374',t:'MTc0MDcxNTQ5Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 